Primary and secondary end points were demonstrated in a phase 3 trial of subcutaneous marstacimab as treatment for patients ...

Pfizer's Hympavzi meets key phase III goals, demonstrating a significant reduction in bleeding in hemophilia patients with ...

Pfizer said on Thursday its hemophilia therapy, Hympavzi, met the main goal of a late-stage study in patients with certain ...

Pfizer's Hympavzi showed superior bleed control in hemophilia A and B patients with inhibitors, reducing bleeding rates and ...

Approved eight months ago for a certain class of patients with both hemophilia A or B, Pfizer’s Hympavzi has now shown its ...

Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 BASIS study (NCT03938792) evaluating ...

The Phase III BASIS trial found that once-weekly subcutaneous Hympavzi reduced treated bleed rates by 93% in patients with ...

Topline data were announced from a phase 3 trial evaluating marstacimab for adults and adolescents living with hemophilia A or B with inhibitors.

Hemophilia A, a lifelong bleeding disorder, often causes spontaneous or injury-related bleeding, most commonly in large ...